Most Favored Nation (MFN) pricing and its impact on pharma asset valuation, M&A, and licensing

table { border-collapse: collapse; font-size: 12px; } table td { border: 1px solid black; padding: 5px; } table tr:first-child td img{ display: inline-block; } table tr:first-child td p{ display: inline-block; vertical-align: middle; } table tr:first-child td:nth-child(2) { background-color: #DAF5F5; color: #2DA1A1; } table tr:first-child td:nth-child(3) { background-color: #CBECFA; color: #0F7199; } table tr:first-child td:nth-child(4) { background-color: #E4E6F5; color: #2D3476; } table tr:nth-child(2) td img{ display: inline-block; width: 15px !important; height: 15px !important; margin-right: 10px; } table tr:not(:first-child) td:first-child { background-color: #4A5F6B; color: white; } table tr:nth-child(2) td p{ display: inline-block; margin-bottom: 0; }

Most Favored Nation (MFN) pricing is bringing global pricing benchmarks into US drug pricing discussions, with meaningful implications for pharma asset valuation and deal economics. Yet the biggest blind spot is how…